25 XP   0   0   10

Anika Therapeutics Inc
Buy, Hold or Sell?

Let's analyse Anika together

PenkeI guess you are interested in Anika Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Anika Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Anika Therapeutics Inc

I send you an email if I find something interesting about Anika Therapeutics Inc.

Quick analysis of Anika (30 sec.)










What can you expect buying and holding a share of Anika? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
30.0%

What is your share worth?

Current worth
$14.29
Expected worth in 1 year
$-5.45
How sure are you?
70.0%

+ What do you gain per year?

Total Gains per Share
$-19.74
Return On Investment
-77.2%

For what price can you sell your share?

Current Price per Share
$25.57
Expected price per share
$21.66 - $27.31
How sure are you?
50%

1. Valuation of Anika (5 min.)




Live pricePrice per Share (EOD)

$25.57

Intrinsic Value Per Share

$-19.82 - $5.75

Total Value Per Share

$-5.53 - $20.05

2. Growth of Anika (5 min.)




Is Anika growing?

Current yearPrevious yearGrowGrow %
How rich?$212.2m$285.5m-$73.2m-34.5%

How much money is Anika making?

Current yearPrevious yearGrowGrow %
Making money-$82.6m-$14.8m-$67.8m-82.0%
Net Profit Margin-49.6%-9.5%--

How much money comes from the company's main activities?

3. Financial Health of Anika (5 min.)




4. Comparing to competitors in the Medical Instruments & Supplies industry (5 min.)




  Industry Rankings (Medical Instruments & Supplies)  

What can you expect buying and holding a share of Anika? (5 min.)

Welcome investor! Anika's management wants to use your money to grow the business. In return you get a share of Anika.

What can you expect buying and holding a share of Anika?

First you should know what it really means to hold a share of Anika. And how you can make/lose money.

Speculation

The Price per Share of Anika is $25.57. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Anika.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Anika, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $14.29. Based on the TTM, the Book Value Change Per Share is $-4.94 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.10 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Anika.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-5.57-21.8%-5.57-21.8%-1.00-3.9%-1.21-4.7%0.401.6%
Usd Book Value Change Per Share-4.94-19.3%-4.94-19.3%-0.10-0.4%-0.69-2.7%0.522.0%
Usd Dividend Per Share0.000.0%0.000.0%0.020.1%0.030.1%0.010.1%
Usd Total Gains Per Share-4.94-19.3%-4.94-19.3%-0.09-0.3%-0.66-2.6%0.532.1%
Usd Price Per Share22.66-22.66-29.60-37.04-40.06-
Price to Earnings Ratio-4.07--4.07--29.58-19.07-20.55-
Price-to-Total Gains Ratio-4.59--4.59--346.38--66.17--9.99-
Price to Book Ratio1.59-1.59-1.54-2.02-2.47-
Price-to-Total Gains Ratio-4.59--4.59--346.38--66.17--9.99-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share25.57
Number of shares39
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.03
Usd Book Value Change Per Share-4.94-0.69
Usd Total Gains Per Share-4.94-0.66
Gains per Quarter (39 shares)-192.50-25.84
Gains per Year (39 shares)-770.00-103.35
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-770-7805-108-113
20-1540-15509-216-216
30-2310-232014-324-319
40-3080-309018-432-422
50-3850-386023-539-525
60-4620-463027-647-628
70-5390-540032-755-731
80-6160-617036-863-834
90-6930-694041-971-937
100-7700-771045-1079-1040

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%1.02.00.033.3%2.03.00.040.0%7.03.00.070.0%21.010.00.067.7%
Book Value Change Per Share0.01.00.00.0%1.02.00.033.3%2.03.00.040.0%7.03.00.070.0%23.08.00.074.2%
Dividend per Share0.00.01.00.0%2.00.01.066.7%3.00.02.060.0%3.00.07.030.0%4.00.027.012.9%
Total Gains per Share0.01.00.00.0%1.02.00.033.3%2.03.00.040.0%7.03.00.070.0%23.08.00.074.2%

Fundamentals of Anika

About Anika Therapeutics Inc

Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief. The company's joint preservation and restoration product family comprises and orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and Hyalomatrix used for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.

Fundamental data was last updated by Penke on 2024-04-11 00:38:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Anika Therapeutics Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Anika earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Anika to the Medical Instruments & Supplies industry mean.
  • A Net Profit Margin of -49.6% means that $-0.50 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Anika Therapeutics Inc:

  • The MRQ is -49.6%. The company is making a huge loss. -2
  • The TTM is -49.6%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-49.6%TTM-49.6%0.0%
TTM-49.6%YOY-9.5%-40.1%
TTM-49.6%5Y-10.2%-39.4%
5Y-10.2%10Y9.6%-19.8%
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
MRQ-49.6%6.2%-55.8%
TTM-49.6%6.2%-55.8%
YOY-9.5%8.0%-17.5%
5Y-10.2%7.3%-17.5%
10Y9.6%6.8%+2.8%
1.1.2. Return on Assets

Shows how efficient Anika is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Anika to the Medical Instruments & Supplies industry mean.
  • -30.5% Return on Assets means that Anika generated $-0.31 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Anika Therapeutics Inc:

  • The MRQ is -30.5%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -30.5%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-30.5%TTM-30.5%0.0%
TTM-30.5%YOY-4.3%-26.3%
TTM-30.5%5Y-6.4%-24.2%
5Y-6.4%10Y3.2%-9.6%
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
MRQ-30.5%1.3%-31.8%
TTM-30.5%1.4%-31.9%
YOY-4.3%1.9%-6.2%
5Y-6.4%2.2%-8.6%
10Y3.2%2.0%+1.2%
1.1.3. Return on Equity

Shows how efficient Anika is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Anika to the Medical Instruments & Supplies industry mean.
  • -38.9% Return on Equity means Anika generated $-0.39 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Anika Therapeutics Inc:

  • The MRQ is -38.9%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -38.9%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-38.9%TTM-38.9%0.0%
TTM-38.9%YOY-5.2%-33.7%
TTM-38.9%5Y-8.4%-30.5%
5Y-8.4%10Y2.8%-11.2%
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
MRQ-38.9%2.6%-41.5%
TTM-38.9%2.8%-41.7%
YOY-5.2%3.7%-8.9%
5Y-8.4%3.9%-12.3%
10Y2.8%3.9%-1.1%

1.2. Operating Efficiency of Anika Therapeutics Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Anika is operating .

  • Measures how much profit Anika makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Anika to the Medical Instruments & Supplies industry mean.
  • An Operating Margin of -15.3% means the company generated $-0.15  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Anika Therapeutics Inc:

  • The MRQ is -15.3%. The company is operating very inefficient. -2
  • The TTM is -15.3%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-15.3%TTM-15.3%0.0%
TTM-15.3%YOY-12.4%-2.9%
TTM-15.3%5Y-4.3%-11.0%
5Y-4.3%10Y19.8%-24.1%
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
MRQ-15.3%7.9%-23.2%
TTM-15.3%7.6%-22.9%
YOY-12.4%10.9%-23.3%
5Y-4.3%10.1%-14.4%
10Y19.8%10.5%+9.3%
1.2.2. Operating Ratio

Measures how efficient Anika is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Medical Instruments & Supplies industry mean).
  • An Operation Ratio of 1.15 means that the operating costs are $1.15 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Anika Therapeutics Inc:

  • The MRQ is 1.153. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.153. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.153TTM1.1530.000
TTM1.153YOY1.124+0.029
TTM1.1535Y1.043+0.110
5Y1.04310Y0.802+0.241
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
MRQ1.1531.1530.000
TTM1.1531.168-0.015
YOY1.1241.105+0.019
5Y1.0431.097-0.054
10Y0.8021.056-0.254

1.3. Liquidity of Anika Therapeutics Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Anika is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Medical Instruments & Supplies industry mean).
  • A Current Ratio of 5.26 means the company has $5.26 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Anika Therapeutics Inc:

  • The MRQ is 5.258. The company is very able to pay all its short-term debts. +2
  • The TTM is 5.258. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ5.258TTM5.2580.000
TTM5.258YOY6.074-0.816
TTM5.2585Y7.257-1.999
5Y7.25710Y12.290-5.033
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
MRQ5.2582.302+2.956
TTM5.2582.333+2.925
YOY6.0742.588+3.486
5Y7.2572.627+4.630
10Y12.2902.623+9.667
1.3.2. Quick Ratio

Measures if Anika is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Anika to the Medical Instruments & Supplies industry mean.
  • A Quick Ratio of 3.50 means the company can pay off $3.50 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Anika Therapeutics Inc:

  • The MRQ is 3.504. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 3.504. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ3.504TTM3.5040.000
TTM3.504YOY5.574-2.070
TTM3.5045Y6.221-2.717
5Y6.22110Y12.133-5.912
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
MRQ3.5041.098+2.406
TTM3.5041.127+2.377
YOY5.5741.306+4.268
5Y6.2211.430+4.791
10Y12.1331.533+10.600

1.4. Solvency of Anika Therapeutics Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Anika assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Anika to Medical Instruments & Supplies industry mean.
  • A Debt to Asset Ratio of 0.22 means that Anika assets are financed with 21.6% credit (debt) and the remaining percentage (100% - 21.6%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Anika Therapeutics Inc:

  • The MRQ is 0.216. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.216. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.216TTM0.2160.000
TTM0.216YOY0.182+0.034
TTM0.2165Y0.191+0.025
5Y0.19110Y0.134+0.057
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2160.357-0.141
TTM0.2160.360-0.144
YOY0.1820.353-0.171
5Y0.1910.365-0.174
10Y0.1340.371-0.237
1.4.2. Debt to Equity Ratio

Measures if Anika is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Anika to the Medical Instruments & Supplies industry mean.
  • A Debt to Equity ratio of 27.5% means that company has $0.27 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Anika Therapeutics Inc:

  • The MRQ is 0.275. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.275. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.275TTM0.2750.000
TTM0.275YOY0.223+0.052
TTM0.2755Y0.239+0.036
5Y0.23910Y0.161+0.078
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2750.541-0.266
TTM0.2750.561-0.286
YOY0.2230.551-0.328
5Y0.2390.653-0.414
10Y0.1610.669-0.508

2. Market Valuation of Anika Therapeutics Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Anika generates.

  • Above 15 is considered overpriced but always compare Anika to the Medical Instruments & Supplies industry mean.
  • A PE ratio of -4.07 means the investor is paying $-4.07 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Anika Therapeutics Inc:

  • The EOD is -4.593. Based on the earnings, the company is expensive. -2
  • The MRQ is -4.071. Based on the earnings, the company is expensive. -2
  • The TTM is -4.071. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-4.593MRQ-4.071-0.523
MRQ-4.071TTM-4.0710.000
TTM-4.071YOY-29.582+25.511
TTM-4.0715Y19.069-23.139
5Y19.06910Y20.551-1.483
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
EOD-4.59314.408-19.001
MRQ-4.07115.934-20.005
TTM-4.07116.376-20.447
YOY-29.58222.147-51.729
5Y19.06920.830-1.761
10Y20.55125.069-4.518
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Anika Therapeutics Inc:

  • The EOD is -52.628. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -46.639. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -46.639. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-52.628MRQ-46.639-5.989
MRQ-46.639TTM-46.6390.000
TTM-46.639YOY-142.852+96.214
TTM-46.6395Y11.063-57.702
5Y11.06310Y20.873-9.810
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
EOD-52.6289.511-62.139
MRQ-46.6399.241-55.880
TTM-46.6390.922-47.561
YOY-142.8523.453-146.305
5Y11.0635.897+5.166
10Y20.873-0.177+21.050
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Anika is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Medical Instruments & Supplies industry mean).
  • A PB ratio of 1.59 means the investor is paying $1.59 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Anika Therapeutics Inc:

  • The EOD is 1.789. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.585. Based on the equity, the company is underpriced. +1
  • The TTM is 1.585. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.789MRQ1.585+0.204
MRQ1.585TTM1.5850.000
TTM1.585YOY1.539+0.046
TTM1.5855Y2.023-0.438
5Y2.02310Y2.468-0.445
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
EOD1.7892.448-0.659
MRQ1.5852.753-1.168
TTM1.5852.691-1.106
YOY1.5393.294-1.755
5Y2.0233.563-1.540
10Y2.4684.227-1.759
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Anika Therapeutics Inc.

3.1. Institutions holding Anika Therapeutics Inc

Institutions are holding 94.24% of the shares of Anika Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Trigran Investments Inc14.40454.6672139054-77965-3.5167
2023-12-31BlackRock Inc9.31910.00081383877-32258-2.2779
2023-12-31Caligan Partners LP7.28198.2637108136000
2023-12-31Dimensional Fund Advisors, Inc.5.53170.0054821452-38683-4.4973
2023-12-31Vanguard Group Inc5.14510.0004764045-3752-0.4887
2023-12-31Renaissance Technologies Corp3.80020.0198564329-24300-4.1282
2023-12-31BOOTHBAY FUND MANAGEMENT, LLC3.43110.2947509522-108080-17.4999
2023-12-31Morgan Stanley - Brokerage Accounts3.26660.00148509324029198.1573
2023-12-31Capital Management Corp2.39421.5826355534271309322.1241
2023-12-31Acadian Asset Management LLC2.25580.0294334991-1067-0.3175
2023-12-31Millennium Management LLC2.20640.0032327642-246897-42.9731
2023-12-31Geode Capital Management, LLC2.14760.0008318913130534.2676
2023-12-31State Street Corporation2.08110.0003309041-29630-8.7489
2023-12-31Nuveen Asset Management, LLC1.78770.001926547612836993.6269
2023-12-31Arrowstreet Capital Limited Partnership1.49840.00532225108339659.948
2023-12-31Invenomic Capital Management, LP1.41640.2174210332116679124.5865
2023-12-31Alta Fundamental Advisers LLC1.29661.97151925441925440
2023-09-30D. E. Shaw & Co LP1.29340.00371920654838833.6783
2023-12-31Goldman Sachs Group Inc1.08740.00031614847898095.7287
2023-12-31Northern Trust Corp0.92540.0006137420-9037-6.1704
Total 72.570617.069810776684+601340+5.6%

3.2. Funds holding Anika Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Vanguard Total Stock Mkt Idx Inv2.99280.000743873900
2024-02-29iShares Russell 2000 ETF2.42650.0139355718-58-0.0163
2023-12-31CMC All-Cap Growth2.42522.10123555343317291393.5266
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr1.57340.0055230662-354-0.1532
2023-12-31CMC SMID1.53396.195224865176675366.6217
2023-10-31Invenomic Institutional1.14560.21241679501679500
2024-01-31CREF Stock R11.09670.0032160781-61390-27.6319
2023-12-31Fidelity Small Cap Index0.98550.012914447115481.0831
2024-01-31DFA US Targeted Value I0.93650.025137286-6813-4.728
2024-02-01iShares Russell 2000 Value ETF0.93310.02711367931740.1274
2024-02-29Franklin MicroCap Value A0.88211.522612931500
2024-01-31DFA US Micro Cap I0.77340.039211337400
2024-02-29Dimensional US Targeted Value ETF0.63180.02369261500
2024-02-29State St Russell Sm/Mid Cp® Indx NL Cl C0.60130.0051881566000.6853
2024-01-31DFA US Small Cap I0.56080.01318221900
2024-01-31Fidelity Extended Market Index0.55140.00538083000
2024-02-29Schwab US Small-Cap ETF™0.46820.01046864500
2024-01-31DFA US Small Cap Value I0.41640.00956103800
2024-02-29State St Russell Sm Cap® Indx SL Cl I0.37670.01425522700
2024-02-29Vanguard Russell 2000 ETF0.36640.01375371442728.6404
Total 21.677710.25363177932+614333+19.3%

3.3. Insider Transactions

Insiders are holding 3.254% of the shares of Anika Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2022-05-11David ColleranBUY150021.37
2022-03-14David ColleranBUY150026.65
2022-03-11Cheryl R BlanchardBUY810025.57
2022-03-11Jeffery S ThompsonBUY200024.66
2022-03-11Michael L LevitzBUY400024.62
2021-08-11Michael L LevitzBUY285040.21
2021-05-12Raymond J LandSELL200042.6

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Anika Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---4.936-4.9360%-0.102-98%-0.692-86%0.516-1057%
Book Value Per Share--14.29414.2940%19.230-26%18.124-21%16.602-14%
Current Ratio--5.2585.2580%6.074-13%7.257-28%12.290-57%
Debt To Asset Ratio--0.2160.2160%0.182+18%0.191+13%0.134+61%
Debt To Equity Ratio--0.2750.2750%0.223+24%0.239+15%0.161+70%
Dividend Per Share----0%0.017-100%0.029-100%0.015-100%
Eps---5.567-5.5670%-1.001-82%-1.215-78%0.397-1502%
Free Cash Flow Per Share---0.486-0.4860%-0.207-57%0.520-194%1.186-141%
Free Cash Flow To Equity Per Share---0.912-0.9120%-0.534-41%0.117-878%0.685-233%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--5.751--------
Intrinsic Value_10Y_min---19.819--------
Intrinsic Value_1Y_max--1.057--------
Intrinsic Value_1Y_min---0.625--------
Intrinsic Value_3Y_max--2.809--------
Intrinsic Value_3Y_min---3.068--------
Intrinsic Value_5Y_max--4.120--------
Intrinsic Value_5Y_min---6.797--------
Market Cap379711943.000+11%336498734.000336498734.0000%439557040.000-23%550040296.000-39%600842800.090-44%
Net Profit Margin---0.496-0.4960%-0.095-81%-0.102-79%0.096-619%
Operating Margin---0.153-0.1530%-0.124-19%-0.043-72%0.198-177%
Operating Ratio--1.1531.1530%1.124+3%1.043+11%0.802+44%
Pb Ratio1.789+11%1.5851.5850%1.539+3%2.023-22%2.468-36%
Pe Ratio-4.593-13%-4.071-4.0710%-29.582+627%19.069-121%20.551-120%
Price Per Share25.570+11%22.66022.6600%29.600-23%37.040-39%40.058-43%
Price To Free Cash Flow Ratio-52.628-13%-46.639-46.6390%-142.852+206%11.063-522%20.873-323%
Price To Total Gains Ratio-5.180-13%-4.591-4.5910%-346.381+7445%-66.168+1341%-9.991+118%
Quick Ratio--3.5043.5040%5.574-37%6.221-44%12.133-71%
Return On Assets---0.305-0.3050%-0.043-86%-0.064-79%0.032-1044%
Return On Equity---0.389-0.3890%-0.052-87%-0.084-78%0.028-1501%
Total Gains Per Share---4.936-4.9360%-0.085-98%-0.662-87%0.531-1030%
Usd Book Value--212265000.000212265000.0000%285563000.000-26%269138200.000-21%248451209.700-15%
Usd Book Value Change Per Share---4.936-4.9360%-0.102-98%-0.692-86%0.516-1057%
Usd Book Value Per Share--14.29414.2940%19.230-26%18.124-21%16.602-14%
Usd Dividend Per Share----0%0.017-100%0.029-100%0.015-100%
Usd Eps---5.567-5.5670%-1.001-82%-1.215-78%0.397-1502%
Usd Free Cash Flow---7215000.000-7215000.0000%-3077000.000-57%7715400.000-194%17872245.300-140%
Usd Free Cash Flow Per Share---0.486-0.4860%-0.207-57%0.520-194%1.186-141%
Usd Free Cash Flow To Equity Per Share---0.912-0.9120%-0.534-41%0.117-878%0.685-233%
Usd Market Cap379711943.000+11%336498734.000336498734.0000%439557040.000-23%550040296.000-39%600842800.090-44%
Usd Price Per Share25.570+11%22.66022.6600%29.600-23%37.040-39%40.058-43%
Usd Profit---82667000.000-82667000.0000%-14859000.000-82%-18036200.000-78%6198147.900-1434%
Usd Revenue--166662000.000166662000.0000%156236000.000+7%143151800.000+16%123670683.900+35%
Usd Total Gains Per Share---4.936-4.9360%-0.085-98%-0.662-87%0.531-1030%
 EOD+5 -3MRQTTM+0 -0YOY+3 -325Y+6 -2910Y+6 -29

4.2. Fundamental Score

Let's check the fundamental score of Anika Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-4.593
Price to Book Ratio (EOD)Between0-11.789
Net Profit Margin (MRQ)Greater than0-0.496
Operating Margin (MRQ)Greater than0-0.153
Quick Ratio (MRQ)Greater than13.504
Current Ratio (MRQ)Greater than15.258
Debt to Asset Ratio (MRQ)Less than10.216
Debt to Equity Ratio (MRQ)Less than10.275
Return on Equity (MRQ)Greater than0.15-0.389
Return on Assets (MRQ)Greater than0.05-0.305
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Anika Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5050.201
Ma 20Greater thanMa 5025.697
Ma 50Greater thanMa 10025.437
Ma 100Greater thanMa 20024.171
OpenGreater thanClose25.590
Total5/5 (100.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets270,632
Total Liabilities58,367
Total Stockholder Equity212,265
 As reported
Total Liabilities 58,367
Total Stockholder Equity+ 212,265
Total Assets = 270,632

Assets

Total Assets270,632
Total Current Assets163,309
Long-term Assets107,323
Total Current Assets
Cash And Cash Equivalents 72,867
Net Receivables 35,961
Inventory 46,386
Other Current Assets 8,095
Total Current Assets  (as reported)163,309
Total Current Assets  (calculated)163,309
+/-0
Long-term Assets
Property Plant Equipment 74,965
Goodwill 7,571
Intangible Assets 4,626
Long-term Assets Other 14,046
Long-term Assets  (as reported)107,323
Long-term Assets  (calculated)101,208
+/- 6,115

Liabilities & Shareholders' Equity

Total Current Liabilities31,059
Long-term Liabilities27,308
Total Stockholder Equity212,265
Total Current Liabilities
Short-term Debt 2,133
Accounts payable 9,860
Other Current Liabilities 17,826
Total Current Liabilities  (as reported)31,059
Total Current Liabilities  (calculated)29,819
+/- 1,240
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt26,904
Long-term Liabilities Other 404
Long-term Liabilities  (as reported)27,308
Long-term Liabilities  (calculated)27,308
+/- 0
Total Stockholder Equity
Common Stock147
Retained Earnings 128,052
Accumulated Other Comprehensive Income -5,943
Other Stockholders Equity 90,009
Total Stockholder Equity (as reported)212,265
Total Stockholder Equity (calculated)212,265
+/-0
Other
Capital Stock147
Cash and Short Term Investments 72,867
Common Stock Shares Outstanding 14,656
Current Deferred Revenue1,240
Liabilities and Stockholders Equity 270,632
Net Debt -43,830
Net Invested Capital 212,265
Net Working Capital 132,250
Property Plant and Equipment Gross 122,634
Short Long Term Debt Total 29,037



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-312006-12-312005-12-312004-12-312003-12-312002-12-312001-12-312000-12-311999-12-311998-12-311997-12-311996-12-311995-12-311994-12-311993-12-31
> Total Assets 
9,600
7,700
8,000
6,900
28,700
32,400
32,500
28,979
22,916
20,086
21,873
59,538
62,618
68,114
79,497
95,821
130,702
128,937
132,844
142,069
156,042
193,996
235,748
240,246
282,617
278,993
330,710
365,605
347,535
349,128
270,632
270,632349,128347,535365,605330,710278,993282,617240,246235,748193,996156,042142,069132,844128,937130,70295,82179,49768,11462,61859,53821,87320,08622,91628,97932,50032,40028,7006,9008,0007,7009,600
   > Total Current Assets 
8,100
6,300
6,600
6,100
27,800
29,500
22,900
25,349
19,568
17,944
20,539
49,083
52,410
57,606
52,443
55,830
49,805
56,322
64,138
77,384
94,592
139,025
176,433
170,440
206,327
202,943
235,747
177,383
168,528
169,547
163,309
163,309169,547168,528177,383235,747202,943206,327170,440176,433139,02594,59277,38464,13856,32249,80555,83052,44357,60652,41049,08320,53917,94419,56825,34922,90029,50027,8006,1006,6006,3008,100
       Cash And Cash Equivalents 
5,100
2,600
2,800
2,700
22,700
10,700
6,400
8,266
9,065
11,002
14,592
39,339
44,747
47,167
35,904
43,194
24,427
28,202
35,777
44,067
63,333
100,156
110,707
104,261
133,256
89,042
157,463
95,817
94,386
86,327
72,867
72,86786,32794,38695,817157,46389,042133,256104,261110,707100,15663,33344,06735,77728,20224,42743,19435,90447,16744,74739,33914,59211,0029,0658,2666,40010,70022,7002,7002,8002,6005,100
       Short-term Investments 
0
0
0
0
0
0
8,200
10,040
3,994
2,500
818
0
0
0
3,502
0
0
0
0
0
0
6,750
27,751
20,500
24,000
69,972
27,480
2,501
0
34,627
0
034,62702,50127,48069,97224,00020,50027,7516,7500000003,5020008182,5003,99410,0408,200000000
       Net Receivables 
300
200
200
500
1,900
3,000
2,100
1,692
2,241
1,198
1,421
2,354
2,066
3,510
5,796
5,418
11,831
14,820
17,308
21,462
18,737
17,152
21,652
27,598
23,825
20,775
23,079
24,102
29,843
34,627
35,961
35,96134,62729,84324,10223,07920,77523,82527,59821,65217,15218,73721,46217,30814,82011,8315,4185,7963,5102,0662,3541,4211,1982,2411,6922,1003,0001,900500200200300
       Inventory 
2,600
3,400
3,300
2,500
2,500
3,500
5,500
4,738
3,727
2,924
3,627
4,227
3,271
5,396
4,390
5,520
8,441
8,950
7,302
8,283
10,997
12,407
14,938
15,983
22,035
21,300
21,995
46,209
36,010
39,765
46,386
46,38639,76536,01046,20921,99521,30022,03515,98314,93812,40710,9978,2837,3028,9508,4415,5204,3905,3963,2714,2273,6272,9243,7274,7385,5003,5002,5002,5003,3003,4002,600
       Other Current Assets 
100
100
300
400
700
12,300
700
613
540
320
899
3,163
2,326
1,533
2,851
1,699
5,105
4,351
3,750
3,571
1,525
2,560
1,385
2,098
3,211
1,854
1,441
8,754
8,289
8,828
8,095
8,0958,8288,2898,7541,4411,8543,2112,0981,3852,5601,5253,5713,7504,3515,1051,6992,8511,5332,3263,16389932054061370012,300700400300100100
   > Long-term Assets 
1,500
1,400
1,400
800
900
2,900
9,600
3,630
3,348
2,143
1,334
10,455
10,208
10,508
27,054
39,990
80,897
72,615
68,707
64,685
61,450
54,971
59,315
69,806
76,290
76,050
96,404
188,222
179,007
179,581
107,323
107,323179,581179,007188,22296,40476,05076,29069,80659,31554,97161,45064,68568,70772,61580,89739,99027,05410,50810,20810,4551,3342,1433,3483,6309,6002,9009008001,4001,4001,500
       Property Plant Equipment 
1,500
1,400
1,400
800
800
2,600
3,500
3,123
2,947
1,941
1,191
955
2,096
3,018
19,370
32,247
35,748
36,981
36,470
35,113
32,939
31,669
40,108
52,296
56,183
54,111
73,647
73,232
68,559
78,975
74,965
74,96578,97568,55973,23273,64754,11156,18352,29640,10831,66932,93935,11336,47036,98135,74832,24719,3703,0182,0969551,1911,9412,9473,1233,5002,6008008001,4001,4001,500
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
995
936
7,652
9,092
8,883
9,066
9,444
8,339
7,482
7,214
8,218
7,851
7,694
8,413
7,781
7,339
7,571
7,5717,3397,7818,4137,6947,8518,2187,2147,4828,3399,4449,0668,8839,0927,65293699500000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
995
936
33,577
25,764
23,149
20,335
18,998
14,895
11,656
10,227
10,635
9,191
7,585
91,157
82,382
74,599
4,626
4,62674,59982,38291,1577,5859,19110,63510,22711,65614,89518,99820,33523,14925,76433,57793699500000000000000
       Other Assets 
0
0
0
0
0
0
0
507
401
201
143
9,500
8,112
7,490
6,689
6,807
3,919
777
205
171
69
69
69
69
1,254
4,897
-1,441
38,039
20,285
18,668
0
018,66820,28538,039-1,4414,8971,254696969691712057773,9196,8076,6897,4908,1129,5001432014015070000000
> Total Liabilities 
2,900
2,300
2,200
1,900
2,500
2,500
6,800
2,266
2,812
3,023
3,889
29,175
24,726
22,626
24,536
35,064
48,558
43,747
38,082
33,144
20,408
15,899
24,900
17,473
19,126
15,381
42,332
93,205
60,450
63,565
58,367
58,36763,56560,45093,20542,33215,38119,12617,47324,90015,89920,40833,14438,08243,74748,55835,06424,53622,62624,72629,1753,8893,0232,8122,2666,8002,5002,5001,9002,2002,3002,900
   > Total Current Liabilities 
1,300
800
1,700
1,800
2,400
2,400
4,000
2,266
2,812
3,023
2,089
6,948
5,826
5,461
10,637
9,033
16,535
19,370
14,538
14,453
9,283
5,973
17,278
8,799
13,073
11,289
16,277
36,867
29,795
27,914
31,059
31,05927,91429,79536,86716,27711,28913,0738,79917,2785,9739,28314,45314,53819,37016,5359,03310,6375,4615,8266,9482,0893,0232,8122,2664,0002,4002,4001,8001,7008001,300
       Short-term Debt 
0
0
1,000
0
0
0
0
0
0
1,703
1,297
0
0
1,574
2,760
1,600
1,600
1,600
1,600
1,600
0
0
-66
-48
0
0
1,141
1,585
1,714
2,073
2,133
2,1332,0731,7141,5851,14100-48-66001,6001,6001,6001,6001,6002,7601,574001,2971,7030000001,00000
       Accounts payable 
1,000
500
400
600
1,000
900
600
871
955
845
349
791
1,277
965
4,867
2,375
6,367
9,694
4,300
2,342
2,794
1,201
8,302
2,303
6,747
3,143
3,832
8,984
7,633
9,074
9,860
9,8609,0747,6338,9843,8323,1436,7472,3038,3021,2012,7942,3424,3009,6946,3672,3754,8679651,2777913498459558716009001,0006004005001,000
       Other Current Liabilities 
300
300
300
1,200
1,400
1,500
3,400
1,396
1,842
326
65
2,041
1,719
17
204
2,325
5,816
5,376
5,772
7,636
6,308
4,748
8,976
6,496
6,326
8,146
11,304
13,090
4,315
16,767
17,826
17,82616,7674,31513,09011,3048,1466,3266,4968,9764,7486,3087,6365,7725,3765,8162,325204171,7192,041653261,8421,3963,4001,5001,4001,200300300300
   > Long-term Liabilities 
1,600
1,500
500
100
100
100
2,800
871
970
993
1,800
22,227
18,900
17,164
13,898
26,031
32,023
24,377
23,543
18,691
11,125
9,926
7,622
8,674
6,053
4,092
26,055
56,338
30,655
35,651
27,308
27,30835,65130,65556,33826,0554,0926,0538,6747,6229,92611,12518,69123,54324,37732,02326,03113,89817,16418,90022,2271,8009939708712,8001001001005001,5001,600
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
9,600
0
0
0
0
0
0
0
0
0
0
0
0
0000000000009,600000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
1,800
22,227
18,900
17,165
13,899
11,631
9,918
6,960
6,568
3,694
3,188
996
7,622
8,674
6,053
4,092
4,688
35,459
11,415
6,834
0
06,83411,41535,4594,6884,0926,0538,6747,6229963,1883,6946,5686,9609,91811,63113,89917,16518,90022,2271,8000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
12,395
2,153
0
9,032
6,841
6,596
5,393
3,542
4,331
11,895
10,157
6,436
0
06,43610,15711,8954,3313,5425,3936,5966,8419,03202,15312,395000000000000000000
> Total Stockholder Equity
6,700
5,400
5,800
5,000
26,200
29,900
25,700
26,712
20,104
17,064
17,984
30,363
37,892
45,488
54,961
60,757
82,144
85,190
94,763
108,925
135,634
178,097
210,848
222,773
263,491
263,612
288,378
272,400
287,085
285,563
212,265
212,265285,563287,085272,400288,378263,612263,491222,773210,848178,097135,634108,92594,76385,19082,14460,75754,96145,48837,89230,36317,98417,06420,10426,71225,70029,90026,2005,0005,8005,4006,700
   Common Stock
0
0
0
0
0
0
100
100
100
100
100
103
105
108
112
114
134
135
136
139
143
149
150
146
147
142
143
143
144
146
147
147146144143143142147146150149143139136135134114112108105103100100100100100000000
   Retained Earnings 
-500
-1,900
-3,900
-9,400
-6,000
-1,700
-4,800
-4,599
-11,357
-14,397
-13,569
-2,379
3,514
8,118
14,153
17,782
21,470
25,786
34,252
46,010
66,584
104,904
135,662
168,209
199,511
218,233
245,426
221,444
225,578
210,719
128,052
128,052210,719225,578221,444245,426218,233199,511168,209135,662104,90466,58446,01034,25225,78621,47017,78214,1538,1183,514-2,379-13,569-14,397-11,357-4,599-4,800-1,700-6,000-9,400-3,900-1,900-500
   Accumulated Other Comprehensive Income -5,943-6,443-5,718-4,542-5,898-5,526-4,784-7,317-6,649-4,495-1,699-2,655-3,067-2,548-11,425-10,190-8,732-10,237-9,853-9,394-8,684-7,678-6,583-245-600-3,800-3,300-3,500-2,900-2,600-2,400
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
63,441
0
0
77,540
81,685
61,735
68,617
50,763
48,707
55,355
67,081
81,141
0
081,14167,08155,35548,70750,76368,61761,73581,68577,5400063,441000000000000000000
   Treasury Stock00000000000000000000-27-280-280-2800000000
   Other Stockholders Equity 
9,600
9,900
10,300
11,800
35,500
35,400
31,000
31,456
37,944
39,039
40,137
42,033
44,126
47,500
49,428
53,051
71,965
61,818
63,441
65,431
70,606
77,540
81,685
61,735
68,617
50,763
48,707
55,355
67,081
81,141
90,009
90,00981,14167,08155,35548,70750,76368,61761,73581,68577,54070,60665,43163,44161,81871,96553,05149,42847,50044,12642,03340,13739,03937,94431,45631,00035,40035,50011,80010,3009,9009,600



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue166,662
Cost of Revenue-63,574
Gross Profit103,088103,088
 
Operating Income (+$)
Gross Profit103,088
Operating Expense-128,537
Operating Income-25,449-25,449
 
Operating Expense (+$)
Research Development32,690
Selling General Administrative98,561
Selling And Marketing Expenses0
Operating Expense128,537131,251
 
Net Interest Income (+$)
Interest Income0
Interest Expense-2,312
Other Finance Cost-4,323
Net Interest Income2,011
 
Pretax Income (+$)
Operating Income-25,449
Net Interest Income2,011
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-85,32734,429
EBIT - interestExpense = -27,761
-85,327
-80,355
Interest Expense2,312
Earnings Before Interest and Taxes (EBIT)-25,449-83,015
Earnings Before Interest and Taxes (EBITDA)-11,215
 
After tax Income (+$)
Income Before Tax-85,327
Tax Provision--3,939
Net Income From Continuing Ops-24,575-81,388
Net Income-82,667
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses192,111
Total Other Income/Expenses Net-59,878-2,011
 

Technical Analysis of Anika
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Anika. The general trend of Anika is BULLISH with 71.4% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Anika's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (71.4%) Bearish trend (-71.4%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Anika Therapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 26.04 < 26.85 < 27.31.

The bearish price targets are: 25.00 > 24.90 > 21.66.

Tweet this
Anika Therapeutics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Anika Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 12/14.
The longshort score for the Moving Averages is 10/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Anika Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Anika Therapeutics Inc. The current macd is 0.09809582.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Anika price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Anika. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Anika price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Anika Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartAnika Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Anika Therapeutics Inc. The current adx is 11.03.

The long score for the Directional Movement Index (DMI) is 1/7.
The longshort score for the Directional Movement Index (DMI) is 1/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Anika shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Anika Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Anika Therapeutics Inc. The current sar is 24.83.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Anika Therapeutics Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Anika Therapeutics Inc. The current rsi is 50.20. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 3/13.
The longshort score for the Relative Strength Index (RSI) is 2/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending down: The RSI is trending down. -1
Anika Therapeutics Inc Daily Relative Strength Index (RSI) ChartAnika Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Anika Therapeutics Inc. The current phase is Correction in bull market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Anika price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Anika Therapeutics Inc Daily Stochastic Oscillator ChartAnika Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Anika Therapeutics Inc. The current cci is -41.8613962.

Anika Therapeutics Inc Daily Commodity Channel Index (CCI) ChartAnika Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Anika Therapeutics Inc. The current cmo is -4.12827061.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Anika Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartAnika Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Anika Therapeutics Inc. The current willr is -56.49350649.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Anika is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Anika Therapeutics Inc Daily Williams %R ChartAnika Therapeutics Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Anika Therapeutics Inc.

Anika Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Anika Therapeutics Inc. The current atr is 0.62363354.

Anika Therapeutics Inc Daily Average True Range (ATR) ChartAnika Therapeutics Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Anika Therapeutics Inc. The current obv is -3,358,190.

Anika Therapeutics Inc Daily On-Balance Volume (OBV) ChartAnika Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Anika Therapeutics Inc. The current mfi is 57.03.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Anika Therapeutics Inc Daily Money Flow Index (MFI) ChartAnika Therapeutics Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Anika Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-05STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-07STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-22SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-02STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-04CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-05CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-11CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-12STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-16SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-17STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-23CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-24MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-25SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-30RSI SHORT ENTRY LONG CLOSE70 crossover to downside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-31ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-02CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-13SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-14CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-15STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-16MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-22SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-23BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-29MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-01MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-04CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-03-06STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-13STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-14DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-15CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-25CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-26STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-27WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-01SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-04-03MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-04-04DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-04-08CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-09DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-11STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-12DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-16DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-04-17CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-18STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-19STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-24STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-25STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside

6.3. Candlestick Patterns

Anika Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Anika Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5050.201
Ma 20Greater thanMa 5025.697
Ma 50Greater thanMa 10025.437
Ma 100Greater thanMa 20024.171
OpenGreater thanClose25.590
Total5/5 (100.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Anika with someone you think should read this too:
  • Are you bullish or bearish on Anika? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Anika? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Anika Therapeutics Inc

I send you an email if I find something interesting about Anika Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Anika Therapeutics Inc.

Receive notifications about Anika Therapeutics Inc in your mailbox!